Myeloperoxidase
Myeloperoxidase (MPO) is an inflammation-associated heme enzyme involved in oxidative processes.
Myeloperoxidase (MPO) is an inflammation-associated heme enzyme involved in oxidative processes. It is particularly relevant to neutrophil biology and has been linked to cardiovascular oxidative stress, inflammatory mechanisms, and cancer progression. Because MPO activity can be measured in biological samples, the enzyme is studied both as a mechanistic mediator and as a potential biomarker of inflammatory activity.
MPO is also being investigated as a pharmacological target. Recent work has examined selective MPO inhibition, including the clinical-development candidate mitiperstat, as well as activity-based analytical methods for detecting MPO in complex samples. Its disease relevance has been explored alongside reactive oxygen species, oxidative stress, proinflammatory cytokines such as interleukin-1β (IL-1β), Interleukin-6 (IL-6), interleukin-17A (IL-17A), and tumor necrosis factor-α (TNF-α), and inflammatory mediators including matrix metallopeptidase 8 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB).
Where the papers sit
11 papers from the last 6 months study myeloperoxidase directly · updated from PubMed 15 Nov 2026
Study type 1 clinical trial · 2 observational · 6 human data · 2 preclinical
Themes 3 themes · 1 new direction
-
MPO in Kidney Disease
MPO and neutrophil elastase are being linked to renal inflammation across ANCA-associated glomerulonephritis and diabetic kidney disease. Early ANCA testing supports diagnosis, while stage-specific MPO and NE mRNA track albuminuria and disease burden. Urine Albumin-to-Creatinine Ratio remains a recurring clinical endpoint. The evidence supports biomarker use, but the relationship between MPO activity and progression remains open.
3 papers · 27.3%
-
MPO Detection Assays
MPO measurement is moving toward highly sensitive, amplified assays suited to serum and point-of-care testing. Aptamer control paired with RCA-CRISPR/Cas12a enables fluorescence and lateral-flow readouts, while DNA nanowires and MXene-gold sensors support electrochemical detection. Trans-cleavage amplification improves detection limits, with interference and heme compatibility remaining practical constraints. Independent validation in complex clinical samples is the next step.
3 papers · 27.3%
-
Others — MPO in Disease and Therapy
MPO is being used across unrelated translational settings, including inhibitor discovery, atherosclerosis risk assessment, cancer drug delivery and joint treatment. Inhibitor studies emphasize pharmacophore modeling and molecular dynamics, whereas Fe3O4 nanozymes combine peroxidase-like activity with doxorubicin delivery. Clinical work examines MPO with granulocyte colony-stimulating factor in intracranial plaque and in synovial fluid after regenerative injections. CAR-engineered progenitors broaden the cluster into cellular immunotherapy without establishing a shared direction.
5 papers · 45.5%
Myeloperoxidase regulates granulocyte-monocyte progenitor expansion and enables engineered myeloid immunotherapy
In expanded mouse and human granulocyte-monocyte progenitors, the study found that myeloperoxidase is a regulator of progenitor proliferation rather than merely an inflammatory enzyme, disease-associated biomarker, assay target, or inhibitor target 42320470Jun. This mechanistic role changes MPO from a readout or therapeutic target into a determinant of the expandable myeloid-cell platform: manipulating it could support progenitor production, donor-derived myelopoiesis, and CAR-engineered antitumor macrophage therapies.
Papers
The 11 papers from the last 6 months that study myeloperoxidase directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
MPO in Kidney Disease (3)
- Stage-specific elevation of MPO and NE mRNA expression in diabetic kidney disease and their independent associations with albuminuria. Molecular biology reports · 15 Sept 2026 PMID 42742850
- ANCA testing strategies: A single centre experience over the past decade in a large teaching hospital in the Netherlands. PloS one · 9 Sept 2026 PMID 42715168
- Pediatric case of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with immunoglobulin a deposition diagnosed early through school urinary screening. CEN case reports · 29 Jun 2026 PMID 42371244
MPO Detection Assays (3)
- Serum-compatible aptamer-regulated RCA-CRISPR/Cas12a assay for fluorescence and lateral flow detection of myeloperoxidase. Mikrochimica acta · 1 Oct 2026 PMID 42821128
- Freeze-thaw-directed interfacial assembly of a gold nanoparticle/MXene electrochemical aptamer sensor for antibody-free myeloperoxidase detection. Mikrochimica acta · 18 Sept 2026 PMID 42758247
- DNA Nanowire-Assisted CRISPR/Cas12a Triple Cascade Amplification for Sensitive Detection of Myeloperoxidase Activity. Analytical chemistry · 27 Jul 2026 PMID 42503780
Others — MPO in Disease and Therapy (5)
- Association of Myeloperoxidase and Granulocyte Colony-Stimulating Factor With Intracranial Atherosclerosis Presence and Progression From a Community-Based Study. Journal of the American Heart Association · 20 Aug 2026 PMID 42622237
- QSAR, molecular dynamics, and biological evaluation of novel myeloperoxidase inhibitors via ligand-based pharmacophore modeling as potential anticancer agents. Journal of computer-aided molecular design · 9 Aug 2026 PMID 42572067
- Synovial fluid level of myeloperoxidase enzyme following ultrasound-guided regenerative injections in patients with irreducible temporomandibular disc displacement: a double-blinded parallel randomized clinical trial. BMC oral health · 19 Jul 2026 PMID 42472796
- Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy. Cell · 19 Jun 2026 PMID 42320470
- Casein-coated Fe3O4 nanozymes with enhanced peroxidase-like activity for synergistic doxorubicin delivery and catalytic anticancer therapy. Journal of biotechnology · 28 May 2026 PMID 42208681
By study type
Clinical trials (1)
- Synovial fluid level of myeloperoxidase enzyme following ultrasound-guided regenerative injections in patients with irreducible temporomandibular disc displacement: a double-blinded parallel randomized clinical trial. BMC oral health · 19 Jul 2026 PMID 42472796
Observational studies and case reports (2)
- ANCA testing strategies: A single centre experience over the past decade in a large teaching hospital in the Netherlands. PloS one · 9 Sept 2026 PMID 42715168
- Pediatric case of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with immunoglobulin a deposition diagnosed early through school urinary screening. CEN case reports · 29 Jun 2026 PMID 42371244
Human data, design not indexed (6)
- Serum-compatible aptamer-regulated RCA-CRISPR/Cas12a assay for fluorescence and lateral flow detection of myeloperoxidase. Mikrochimica acta · 1 Oct 2026 PMID 42821128
- Freeze-thaw-directed interfacial assembly of a gold nanoparticle/MXene electrochemical aptamer sensor for antibody-free myeloperoxidase detection. Mikrochimica acta · 18 Sept 2026 PMID 42758247
- Stage-specific elevation of MPO and NE mRNA expression in diabetic kidney disease and their independent associations with albuminuria. Molecular biology reports · 15 Sept 2026 PMID 42742850
- Association of Myeloperoxidase and Granulocyte Colony-Stimulating Factor With Intracranial Atherosclerosis Presence and Progression From a Community-Based Study. Journal of the American Heart Association · 20 Aug 2026 PMID 42622237
- DNA Nanowire-Assisted CRISPR/Cas12a Triple Cascade Amplification for Sensitive Detection of Myeloperoxidase Activity. Analytical chemistry · 27 Jul 2026 PMID 42503780
- Casein-coated Fe3O4 nanozymes with enhanced peroxidase-like activity for synergistic doxorubicin delivery and catalytic anticancer therapy. Journal of biotechnology · 28 May 2026 PMID 42208681
Preclinical: animal, cell and lab studies (2)
- QSAR, molecular dynamics, and biological evaluation of novel myeloperoxidase inhibitors via ligand-based pharmacophore modeling as potential anticancer agents. Journal of computer-aided molecular design · 9 Aug 2026 PMID 42572067
- Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy. Cell · 19 Jun 2026 PMID 42320470
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-09-02. Last written: 2026-09-20 by GPT. Drafted by language models from published abstracts; not medical advice.